Regarding ACTC, I watched that one closely today, but didn't yet bite. It's beginning to look attractive again, but I don't like how the company all of a sudden stopped publishing the float numbers like they used to. My guess is that the A/S count is probably just about maxed out, thus even at .075, ACTC is still valued near $37.5 million dollars and that's pretty steep. I love what they're doing, but stem cell companies are years away from getting anything to market. I do however, think that ACTC will one day be bought out by big pharma.